Market Research Logo

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2018

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2018, provides an overview of the Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) pipeline landscape.

Attention deficit hyperactivity disorder (ADHD) is a group of behavioral symptoms that include inattentiveness, hyperactivity and impulsiveness. Symptoms of ADHD include disorganized work habits, procrastination and inability to sustain attention on tasks or activities. Treatment includes analeptics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 5, 12, 9, 15, 4 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Attention Deficit Hyperactivity Disorder (ADHD) - Overview
Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Attention Deficit Hyperactivity Disorder (ADHD) - Companies Involved in Therapeutics Development
4P-Pharma SAS
Aevi Genomic Medicine Inc
Amarantus Bioscience Holdings Inc
APeT Holding BV
Arcturus Therapeutics Ltd
BCWorld Pharm Co Ltd
BioHealthonomics Inc
Cingulate Therapeutics LLC
Collegium Pharmaceutical Inc
Curemark LLC
DURECT Corp
Heptares Therapeutics Ltd
Highland Therapeutics Inc
IRLAB Therapeutics AB
KemPharm Inc
leon-nanodrugs GmbH
Merck & Co Inc
Novartis AG
Noven Pharmaceuticals Inc
Otsuka Holdings Co Ltd
Otsuka Pharmaceutical Co Ltd
P2D Inc
RespireRx Pharmaceuticals Inc
Reviva Pharmaceuticals Inc
Shionogi & Co Ltd
Shire Plc
SK Biopharmaceuticals Co Ltd
Sunovion Pharmaceuticals Inc
Supernus Pharmaceuticals Inc
Taisho Pharmaceutical Holdings Co Ltd
Tris Pharma Inc
Attention Deficit Hyperactivity Disorder (ADHD) - Drug Profiles
4P-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
atomoxetine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BCWPE-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNC-375 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CB-8411 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
centanafadine SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CM-4612 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CX-717 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dasotraline - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dexmethylphenidate hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dextroamphetamine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dextroamphetamine IR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dextroamphetamine MR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Attention Deficit Hyperactivity Disorder - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eltoprazine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fasoracetam - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
guanfacine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
guanfacine hydrochloride ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
histamine dihydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HTL-1071 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INV-107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KP-415 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KP-484 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Leon-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
levofacetoperane - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lisdexamfetamine dimesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mazindol CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
methylphenidate ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
methylphenidate hydrochloride MR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
methylphenidate hydrochloride SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
modafinil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
molindone hydrochloride ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
niacinamide CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NLS-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NLS-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NLS-8 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OPC-64005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBF-509 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PD-3044 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PFR-08001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PFR-8026 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RP-5063 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SERx-480 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SKL-13865 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target Dopamine, Norepinephrine and Serotonin Transporter for Attention Deficit Hyperactivity Disorder - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate High Affinity Choline Transporter for Attention Deficit Hyperactivity Disorder - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit SLC9A9 for ADHD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRN-110 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TS-141 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
viloxazine hydrochloride ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-0238429 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects
Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products
Attention Deficit Hyperactivity Disorder (ADHD) - Product Development Milestones
Featured News & Press Releases
Jul 19, 2018: Aevi Genomic Medicine Announces Novel Co-crystal Version of AEVI-001
Jul 12, 2018: Ironshore Pharmaceuticals Announces PDUFA Date of August 8, 2018 for HLD200
Jul 09, 2018: KemPharm Announces Top Line Results from KP415.E01 Efficacy and Safety Trial in Children With ADHD
Jun 12, 2018: 4P-Pharma, a recognized actor in the ADHD drug pipeline development
Jun 12, 2018: Aevi Genomic Medicine Provides Update on Sample Size Re-estimation for Phase 2 ASCEND Trial in ADHD
May 10, 2018: KemPharm Announces Positive, Topline Results from an Intravenous Human Abuse Potential Trial with KP415 Prodrug
May 02, 2018: Sunovion to Present Data on dasotraline at the 2018 American Psychiatric Association Annual Meeting
Mar 20, 2018: KemPharm Announces Positive Top line Results from KP415 Pharmacokinetic Study in Children and Adolescents With ADHD
Jan 15, 2018: Cingulate Therapeutics Presents New Data from its First in Human Proof of Concept Trial of CTX-1301 at the 2018 APSARD Annual Meeting
Jan 09, 2018: Cingulate Therapeutics to Present at 10th Annual Biotech Showcase
Jan 09, 2018: Cingulate Therapeutics to Present CTX-1302 at 10th Annual Biotech Showcase
Jan 08, 2018: KemPharm Initiates Pivotal Efficacy Trial of KP415
Jan 04, 2018: Cingulate Therapeutics to Present New Data from its First in Human Proof of Concept Trial of CTX-1301 at the 2018 APSARD Annual Meeting
Dec 18, 2017: RespireRx Pharmaceuticals Publishes Compelling Scientific Evidence Demonstrating the Neurobiological Safety of Ampakine CX717 and Justifying Continued Clinical Development
Nov 16, 2017: KemPharm Completes Successful End-of-Phase 2 Meeting on KP415 with FDA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by 4P-Pharma SAS, H2 2018
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Aevi Genomic Medicine Inc, H2 2018
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Amarantus Bioscience Holdings Inc, H2 2018
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by APeT Holding BV, H2 2018
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Arcturus Therapeutics Ltd, H2 2018
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by BCWorld Pharm Co Ltd, H2 2018
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by BioHealthonomics Inc, H2 2018
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Cingulate Therapeutics LLC, H2 2018
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Collegium Pharmaceutical Inc, H2 2018
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Curemark LLC, H2 2018
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by DURECT Corp, H2 2018
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Heptares Therapeutics Ltd, H2 2018
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Highland Therapeutics Inc, H2 2018
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by IRLAB Therapeutics AB, H2 2018
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by KemPharm Inc, H2 2018
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by leon-nanodrugs GmbH, H2 2018
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Merck & Co Inc, H2 2018
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Novartis AG, H2 2018
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Noven Pharmaceuticals Inc, H2 2018
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Otsuka Holdings Co Ltd, H2 2018
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Otsuka Pharmaceutical Co Ltd, H2 2018
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by P2D Inc, H2 2018
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by RespireRx Pharmaceuticals Inc, H2 2018
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Reviva Pharmaceuticals Inc, H2 2018
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Shionogi & Co Ltd, H2 2018
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Shire Plc, H2 2018
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by SK Biopharmaceuticals Co Ltd, H2 2018
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Sunovion Pharmaceuticals Inc, H2 2018
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Supernus Pharmaceuticals Inc, H2 2018
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H2 2018
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Tris Pharma Inc, H2 2018
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, H2 2018
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, H2 2018 (Contd..1), H2 2018
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, H2 2018 (Contd..2), H2 2018
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, H2 2018 (Contd..3), H2 2018
Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products, H2 2018
List of Figures
Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report